Moleculin Biotech is trading 5.5% down at $2.18 today, extending recent weakness as the stock hits a new 52-week low amid broader market risk-off sentiment.
- The move follows the stock hitting a new 52-week low near $2.11, with selling pressure likely tied to broader market volatility affecting high-beta, early-stage biotech names.
- There is no fresh company-specific news today, suggesting the decline is driven by macro sentiment rather than new internal developments.
- Investors remain cautious regarding the company's ongoing cash burn, potential dilution risks, and heavy dependence on high-risk cancer drug trials.